Ongoing clinical trials are investigating the effect of neratinib (SUMMIT trial; NCT01953926) and afatinib (NCI-MATCH; NCT02465060) in patients with ERBB2-mutant cancers. The gene discussed is ERBB2; the disease is cancer.